Table 4 BCVA changes in subjects with different stages of DME after anti-VEGF treatment.

From: Shifting of the local inflammatory characteristics of diabetic macular edema manifested in SD-OCT after anti-VEGF treatment and associations with system inflammatory bioparameters

Parameters

Median (IQR)

Early DME (n = 37)

Advanced DME (n = 35)

Severe DME (n = 36)

atrophic DME (n = 18)

P-value

Baseline BCVA (logMAR)

0.48(0.39, 0.63)

0.39(0.29, 0.46)a

0.87(0.77, 1.02)a, b

0.95(0.90, 1.04)a, b,c

< 0.001

BCVA after treatment (logMAR)

0.25(0.14, 0.28)

0.33(0.26, 0.38)a

0.71(0.59, 0.81)a, b

1(0.85, 1.07)a, b,c

< 0.001

BCVA changes (logMAR)

− 0.33 (− 0.42, − 0.17)

− 0.04 (− 0.15, 0.02)a

− 0.15(− 0.42, − 0.05)b

0.06(− 0.19, 0.27)a, b,c

< 0.001

P-value

< 0.001

0.012

< 0.001

0.407

 
  1. BCVA best-corrected visual acuity, LogMAR logarithm of the minimum angle of resolution.
  2. ap < 0.008 compared with early DME.
  3. bp < 0.008 compared with advanced DME.
  4. cp < 0.008 compared with severe DME (Bonferroni correction).
Back to article page